Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Denali Therapeutics (DNLI) EBT Margin: 2018-2023

Historic EBT Margin for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2023 value amounting to -7,841.59%.

  • Denali Therapeutics' EBT Margin fell 493912.00% to -7,841.59% in Q3 2023 from the same period last year, while for Sep 2023 it was -122.53%, marking a year-over-year increase of 15829.00%. This contributed to the annual value of -43.93% for FY2023, which is 25661.00% up from last year.
  • Denali Therapeutics' EBT Margin amounted to -7,841.59% in Q3 2023, which was down 20,909.04% from -37.32% recorded in Q2 2023.
  • Over the past 5 years, Denali Therapeutics' EBT Margin peaked at 77.56% during Q4 2020, and registered a low of -7,841.59% during Q3 2023.
  • For the 3-year period, Denali Therapeutics' EBT Margin averaged around -1,439.16%, with its median value being -606.01% (2021).
  • Per our database at Business Quant, Denali Therapeutics' EBT Margin soared by 308,957bps in 2019 and then slumped by 493,912bps in 2023.
  • Denali Therapeutics' EBT Margin (Quarterly) stood at -1,154.75% in 2019, then spiked by 123,231bps to 77.56% in 2020, then slumped by 68,356bps to -606.01% in 2021, then tumbled by 35,367bps to -959.68% in 2022, then slumped by 493,912bps to -7,841.59% in 2023.
  • Its EBT Margin was -7,841.59% in Q3 2023, compared to -37.32% in Q2 2023 and -312.40% in Q1 2023.